Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 2Neoplasms 2Glioblastoma 2Carcinoma, Hepatocellular 2Vulvar Neoplasms 1Vaginal Neoplasms 1Stomach Neoplasms 1Recurrence 1Prostatic Neoplasms 1Penile Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Hepatitis, Chronic 1Hepatitis C 1Head and Neck Squamous Cell Cancer 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Squamous Cell 1Breast Neoplasms 1BRCA1/2 Mutation 1Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

Cisplatin 6pembrolizumab 5fludarabine 5Nivolumab 5Cyclophosphamide 5aldesleukin 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Radiotherapy 3Ipilimumab 3fludarabine phosphate 2entinostat 2cabozantinib 2avelumab 2aflibercept 2Specimen Handling 2CTLA-4 Antigen 2Adoptive Transfer 2vinflunine 1toripalimab 1rocakinogene sifuplasmid 1ripretinib 1oncogene protein E7, Human papillomavirus type 16 1niraparib 1nimotuzumab 1lenvatinib 1enfortumab vedotin 1durvalumab 1dostarlimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Penile Neoplasms × rocakinogene sifuplasmid × Clear all
NCT03439085 2024-07-09

DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers

M.D. Anderson Cancer Center

Phase 2 Terminated
41 enrolled 13 charts
GastrointestinalGenitourinaryGynecologic

Anal Canal Carcinoma, Anus Neoplasms, Uterine Cervical Neoplasms, Neoplasm Metastasis, Neoplasms, Penile Neoplasms, Recurrence, Vaginal Neoplasms, Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡